Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cellsEdris Choupani(Iran University of Medical Sciences), Arshad Hosseini(Iran University of Medical Sciences)PLoS ONEDecember 22, 202210.1371/journal.pone.0279522Cited by 27SaveCiteExport RISWatch citationsRelated PapersThe effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells|PLoS ONE|2024|1